Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 33 Years - Since 1980		THE CURRENT TIME at LC Labs is:
		Search:  Product Pages Only  Entire Site

V-8400 Vincristine, Sulfate Salt, >99%      NEW!

Synonyms:  [LCR sulfate] [Leurocristine sulfate] [Lilly 37231] [22-Oxovincaleukoblastine sulfate] [VCR sulfate] [Vincristine hydrogen sulfate] [Lilly-37231] [LY-37231] [LY 37231] [LY37231] [NSC 67574] [NSC67574]
Related Terms:  [Kyocristine] [Marqibo] [Novopharm] [Oncovin] [Onkovin] [Vincasar PFS] [Vincrex] [Vincrisul]

M.W. 923.04

C46H56N4O10•H2SO4

[2068-78-2]

M.I. 14:  9986

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 60 mg/mL; very poorly soluble in ethanol; soluble in water at 25 mg/mL with warming; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Vincristine, also known as leurocristine, sometimes abbreviated "VCR", is a mitotic inhibitor.

• Treatment with cyclophosphamide, hydroxydaunorubicin (doxorubicin, please see Cat. No. D-4000, Doxorubicin, Hydrochloride Salt and Cat. No. D-4099, Doxorubicin, Free Base), Oncovin® (vincristine), and prednisone (CHOP) has long been the standard therapy for non-Hodgkin's lymphoma.  Improvements have been made to the efficacy of this regimen by increasing the dosing frequency and by adding rituximab immunotherapy to the regimen.  Gisselbrecht, C.  "Current approaches to the treatment of non-Hodgkin's lymphoma."  Hematol. Rep. 3:  e3 (2011).

• ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) has been the standard of treatment for patients with advanced-stage Hodgkin lymphoma (HL).  Kuruvilla, J. "Standard therapy of advanced Hodgkin lymphoma."  Hematology Am. Soc. Hematol. Educ. Program  497-506 (2009).

• Vincristine was metabolized in vitro more efficiently by CYP3A5 than by CYP3A4.  In children with precursor B cell acute lymphoblastic leukemia, CYP3A5 expressers produced more primary metabolite (M1), had lower metabolic ratios of [vincristine]/[M1], and experienced less vincristine-induced peripheral neuropathy when compared to CYP3A5 non-expressers.  Egbelakin, A., et al.  "Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia."  Pediatr. Blood Cancer 56:  361-367 (2011).

• Sixty-three patients with advanced chronic lymphocytic leukemia were treated with vincristine, cyclophosphamide, BCNU, melphalan, and prednisone (M-2 protocol).  Complete remission (CR) and partial response (PR) were achieved in 17% and 44%, respectively.  The median survivals of patients achieving a CR, PR, or no response were 73+, 40, and 14 months, respectively.  Kempin, S., et al.  "Combination chemotherapy of advanced chronic lymphocytic leukemia:  the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone)."  Blood 60:  1110-1121 (1982).

• Exposure of platelets to vincristine resulted in disassembly of microtubules, loss of discoid shape, formation of tubulin crystals, a depressed response to aggregating agents, and reduced secretory activity.  White, J.G. and Rao, G.H.  "Effects of a microtubule stabilizing agent on the response of platelets to vincristine."  Bloo 60:  474-483 (1982).

• Vincristine is the active ingredient in the drug sold under the trade name Oncovin®.  This drug is currently approved in at least one country for use to treat patients with cancers in various types of chemotherapy regimens.  NOTE:  THE VINCRISTINE, SULFATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT ONCOVIN®, AND IS NOT FOR HUMAN USE.

• Related CAS number:  57-22-7 for the free base.

• We tested the purity of Tocris's vincristine product, their Cat. No. 1257, Batch 3A, and found HPLC purity of only 82% instead of the claimed 96%. Proton NMR also showed purity lower than claimed.

• STRUCTURE ERRORS ON WIKIPEDIA AND FOUR VENDORS' WEBSITES:  As of December 21, 2012, the vincristine structures shown on Wikipedia and at least four vendors' (Cayman, Santa Cruz, Selleck, and Sigma) web pages are incorrect in one or more ways.  (We have not checked most other vendors' vincristine structures.)  Also, the vincristine structure shown on Chemblink fails to specify the stereochemistry at two asymmetric carbon atoms.  Finally, the Merck Index Vol. 14 entry for vincristine shows a dashed bond connecting a nitrogen atom and a symmetrically substituted carbon atom; this appears to be a bond that would not normally be shown as embodying stereochemical information, so our structure shows it as a plain single bond.

• Vincristine is the active ingredient in drug products sold under numerous trade names, such as those listed near the top of this page as "Related Terms".  These drug products have been approved in at least one country for use in patients with cancer.  NOTE:  THE VINCRISTINE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT ANY OF THE VINCRISTINE-CONTAINING DRUG PRODUCTS SOLD UNDER VARIOUS TRADE NAMES AND IS NOT FOR HUMAN USE.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.

* We tested the purity of Tocris's vincristine product, their Cat. No. 1257, Batch 3A, and found HPLC purity of only 82% instead of the claimed 96%.  Proton NMR also showed purity lower than claimed.

** Our prices are lower than other vendors', but there is no compromise in quality.  Read how we are able to accomplish this:  Product Quality Discussion.

NOTES:
1.  The purpose of our competitor price comparison tables is to enable our visitors to compare the prices and purities of products of nominally equivalent quality, for vendors whose price and purity claims are openly available from a website or catalog (without a need for the customer to contact the vendor and request a quotation in order to obtain a price and purity for a standard product size).  However, the quality comparisons in these tables are not absolute:  although our product purities are uniformly very high and are established by careful testing of every lot in our laboratories, we cannot and do not vouch for the purities claimed by other vendors in these competitor price comparison tables.  (We do carry out occasional testing of other vendors' products -- see below --  and we have found many instances where vendors' product purities are far below their claimed levels.)  Effective April 1, 2011, our price comparison tables only include products where a purity commitment is found together with sizes and prices on at least one page of the vendor's web site.

2.  Researching and compiling sizes and prices for the >160 competitive vendors and more than 175 products is an expensive and tedious task for our small company.  Thus, we typically only perform revisions of these tables annually or less frequently.  The date and source of each competitive vendor's prices is indicated at the bottom of this page.  Obviously, we make no guarantee that competitive vendor prices will remain unchanged in the interval between our annual revisions.  We may occasionally update individual competitive vendor information and add new competitive vendors as we locate them.

3.  In some circumstances we permanently remove vendors from our price comparison tables.  Circumstances that lead to permanent removal are: 

A.  If a vendor does not honor its advertised price (ignoring small price increases) for one or more products when an order is attempted.  Example:  a vendor listed a compound at $808 for 10 grams on its website price list, but quoted $4,500 per 10 grams upon our inquiry.  That vendor has been permanently removed from our price comparison tables.

B.  If, on a product-by-product basis, our analyses of a vendor's product show purities more than a few percent below the vendor's advertised purities.  Example:  a vendor advertises a purity for 97% for a compound, but repeated elemental analyses show a minimum of 9% inorganic material present, beyond any salt counterion.  Another example: an HPLC analysis at a relevant UV detector wavelength shows 92% purity for a vendor's product for which 98% purity is claimed.  We realize of course that UV absorbances for impurities can be higher than for the main compound, but our products meet our purity commitment of typically >99% irrespective of absorbance factors for impurities, and we apply that standard to products from other vendors.

C.  Again on a product-by-product basis, if a vendor makes no purity claim for a given product, then their product is not shown on that product table.

D.  If we find that, as a pattern, several of a competitive vendor's products fail to meet their advertised purity commitments by significant margins or if a vendor does not provide standard and consistent purity claims for several of its products, then that vendor is permanently removed from all of our competitor price tables.

E.  Finally, if we determine that a vendor has provided fraudulent information on its website, in its literature or on a certificate of analysis, that vendor is permanently removed from all of our price comparison tables.

4.  IMPORTANT:  The presence of a competitive vendor entry in our price comparison tables does not necessarily mean that we have analyzed any of that vendor's products for purity; indeed, in most cases we have not.

5.  Please note:  where necessary, competitor prices are rounded to the nearest whole dollar.

To the best of our knowledge, the prices listed above for our competitors' products were correct as of the dates listed below for the sources of our annual price information update process.

Pricing Sources and Dates:  LC Labs - Current, EMD Chemicals - website - Jan 2013, Sigma-Aldrich - website - Jan 2013, MP Biomedicals - website - Jan 2013, Enzo Life Sciences - website - Jan 2013, Tocris Bioscience - website - Jan 2013, AG Scientific - website - Jan 2013, AntibioticPlus - website - Jan 2013, Axxora - website - Jan 2013, LKT Labs - website - May 2013, Lab Depot - website - Jan 2013, Science Lab - website - Jan 2013, Santa Cruz Biotech - website - Jan 2013, Cayman Chemical - website - Dec 2012, Acros Organics - website - Jan 2013, Cole-Parmer - website - Jan 2013, PGC Scientifics - website - Jan 2013, R&D Systems - website - Jan 2013, Colonial Scientific - website - Jan 2013, AK Scientific - website - Mar 2013, Neobits - website - Mar 2013, Alfa Aesar - website - Mar 2013, Carbone Scientific - website - Jan 2013, JIT Lab Supply - website - Jan 2013, TCASChem Tech - website - Apr 2013, biorbyt.com - website - Jan 2013, Utech Products - website - Sep 2012, ChemReagents.com - website - Jan 2013, Abcam - website - Dec 2012, P212121 - website - Jan 2013, MedKoo BioSciences - website - Apr 2013, AdooQ BioScience - website - Jan 2013, Krackeler Scientific - website - Jan 2013, LabLife - website - Jan 2013, Boston Biochem - website - Jan 2013, Reagent World - website - Dec 2012, Sapphire North America - website - Apr 2013.

^† Note:  AntibioticPlus' product VCR98 is the free base form of this compound.